ImmuPharma (LON:IMM) Trading Up 28.6% - Time to Buy?

Key Points

• ImmuPharma shares surged 28.6% during mid-day trading, reaching a high of GBX 12 ($0.16) with significant trading volume of 17 million shares, nearly double its average volume.
• The company reported a net margin of 3,519.56% despite a negative return on equity of 131.41%, and is expected to have a projected earnings per share of -339.0000022 for the current fiscal year.
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases and has developed a leading program, Lupuzor™, aimed at treating Lupus and other autoimmune conditions.

ImmuPharma plc (LON:IMM - Get Free Report) shares were up 28.6% during mid-day trading on Tuesday . The company traded as high as GBX 12 ($0.16) and last traded at GBX 11.30 ($0.15). Approximately 17,007,168 shares changed hands during trading, an increase of 97% from the average daily volume of 8,614,648 shares. The stock had previously closed at GBX 8.79 ($0.12).

ImmuPharma Stock Performance

The business's fifty day simple moving average is GBX 5.30 and its 200-day simple moving average is GBX 3.58. The firm has a market capitalization of £56.47 million, a PE ratio of -1,269.66 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Sell-side analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.